In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 60 of 293

Sort by

Type: Guidance`Remove $Type: Guidance filter`
Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]	Technology appraisal guidance	TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]	Technology appraisal guidance	6 August 2026
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]	Technology appraisal guidance	28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC

Results per page

10
25
50
All